Mucus may block inhaled antibodies in lung disease
NCT ID NCT06670937
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how mucus from the airways of people with bronchiectasis affects a new inhaled antibody treatment. Researchers will collect sputum samples from 30 adults with stable bronchiectasis and test how well the antibodies can reach and bind to bacteria in the lab. The goal is to understand barriers to this therapy and help design better inhaled treatments for chronic lung infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de Tours
Tours, France, 37044, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mapping patient profiles unlock better breathing therapy for bronchiectasis?
- Can an inhaled drug ease bronchiectasis? a trial seeks answers
- Breathing and qigong: a drug-free approach to easier breathing for damaged lungs?
- Could your own lung cells heal damaged airways? a new trial aims to find out
- New drug CTX-187 takes aim at stubborn bacterial infections
- Lung patients may soon do rehab from home via app